[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-001", "question": "A 3-day-old term neonate presents with progressive cyanosis unresponsive to supplemental oxygen. Echocardiography reveals d-transposition of the great arteries with intact ventricular septum and a restrictive patent foramen ovale. Prostaglandin E1 infusion is initiated but cyanosis persists with oxygen saturation of 55%. The infant is hemodynamically stable with adequate biventricular function. Which of the following is the most appropriate next step in management?", "options": ["Emergent arterial switch operation", "Balloon atrial septostomy", "Extracorporeal membrane oxygenation", "Inhaled nitric oxide therapy", "Atrial septectomy via median sternotomy"], "answer": "B", "answer_index": 1, "explanation": "In d-TGA with intact ventricular septum and restrictive atrial communication, balloon atrial septostomy (Rashkind procedure) is the urgent intervention to improve mixing at the atrial level. PGE1 maintains ductal patency but cannot improve atrial mixing when the foramen ovale is restrictive. Arterial switch is definitive but requires stabilization first. ECMO is reserved for refractory cases after septostomy. Surgical septectomy is more invasive and reserved for failed balloon septostomy.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: The keyed answer B is the correct best answer. Key discriminating clues: 3-day-old term neonate with d-TGA, intact ventricular septum, and restrictive PFO causing severe cyanosis (SpO2 55%) despite PGE1 infusion, while hemodynamically stable. The critical pathophysiology is inadequate atrial-level mixing, which PGE1 cannot overcome when the foramen is restrictive. Balloon atrial septostomy (Rashkind) is the established urgent catheter-based intervention to create adequate atrial mixing and stabilize the neonate before definitive arterial switch repair. Alternative options are appropriately inferior: emergent arterial switch (requires stabilization first), ECMO (reserved for refractory hypoxemia post-septostomy), inhaled nitric oxide (targets pulmonary hypertension, not mixing), and surgical septectomy (invasive, reserved for failed catheter approach). No internal contradictions exist; 'restrictive PFO' is accepted clinical terminology. The item aligns with pediatric cardiology guidelines and classic board expectations. No medical inaccuracies or logical flaws detected. Minimal fix: None required; item is board-ready.\",\"medical_accuracy_score\":  \"5\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: The keyed answer B is the correct best answer. Key discriminating clues: 3-day-old term neonate with d-TGA, intact ventricular septum, and restrictive PFO causing severe cyanosis (SpO2 55%) despite PGE1 infusion, while hemodynamically stable. The critical pathophysiology is inadequate atrial-level mixing, which PGE1 cannot overcome when the foramen is restrictive. Balloon atrial septostomy (Rashkind) is the established urgent catheter-based intervention to create adequate atrial mixing and stabilize the neonate before definitive arterial switch repair. Alternative options are appropriately inferior: emergent arterial switch (requires stabilization first), ECMO (reserved for refractory hypoxemia post-septostomy), inhaled nitric oxide (targets pulmonary hypertension, not mixing), and surgical septectomy (invasive, reserved for failed catheter approach). No internal contradictions exist; 'restrictive PFO' is accepted clinical terminology. The item aligns with pediatric cardiology guidelines and classic board expectations. No medical inaccuracies or logical flaws detected. Minimal fix: None required; item is board-ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-002", "question": "A 58-year-old woman with longstanding rheumatoid arthritis on methotrexate and adalimumab presents with 6 weeks of progressive dyspnea and dry cough. HRCT shows diffuse ground-glass opacities with areas of consolidation in a peribronchovascular distribution. Bronchoalveolar lavage reveals 45% lymphocytes with CD4/CD8 ratio of 0.5. Methotrexate pneumonitis is suspected. Which histopathologic pattern is most commonly associated with methotrexate-induced lung toxicity?", "options": ["Usual interstitial pneumonia", "Diffuse alveolar damage", "Hypersensitivity pneumonitis pattern", "Organizing pneumonia", "Pulmonary alveolar proteinosis"], "answer": "C", "answer_index": 2, "explanation": "Methotrexate-induced lung toxicity most commonly manifests as a hypersensitivity pneumonitis pattern, characterized by lymphocytic alveolitis with low CD4/CD8 ratio, granulomas, and interstitial inflammation. The BAL findings of elevated lymphocytes with inverted CD4/CD8 ratio support this diagnosis. While organizing pneumonia and diffuse alveolar damage can occur, hypersensitivity pneumonitis is the predominant pattern. UIP pattern is more characteristic of RA-ILD itself rather than drug toxicity.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. The stem provides robust discriminators: methotrexate exposure, subacute dyspnea/cough, HRCT showing diffuse ground-glass opacities with peribronchovascular consolidation, and BAL lymphocytosis (45%) with inverted CD4/CD8 ratio (0.5). These findings collectively point to hypersensitivity pneumonitis (HP), which is indeed the most common histopathologic pattern in methotrexate-induced lung toxicity. Alternative options are appropriately inferior: UIP (A) reflects RA-ILD itself, not drug toxicity; DAD (B) and organizing pneumonia (D) are recognized but less frequent methotrexate patterns; pulmonary alveolar proteinosis (E) is unrelated. No logical flaws exist—the stem is internally consistent, provides adequate detail for a single best answer, and the key matches it. Medical accuracy is gold-standard: the HP pattern association is well-established in literature, the BAL profile is correctly characterized, and the rationale accurately distinguishes drug-induced injury from underlying rheumatoid lung disease. The item is clinically realistic and board-relevant. No modifications needed.\",\"medical_accuracy_score\":   \t\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The stem provides robust discriminators: methotrexate exposure, subacute dyspnea/cough, HRCT showing diffuse ground-glass opacities with peribronchovascular consolidation, and BAL lymphocytosis (45%) with inverted CD4/CD8 ratio (0.5). These findings collectively point to hypersensitivity pneumonitis (HP), which is indeed the most common histopathologic pattern in methotrexate-induced lung toxicity. Alternative options are appropriately inferior: UIP (A) reflects RA-ILD itself, not drug toxicity; DAD (B) and organizing pneumonia (D) are recognized but less frequent methotrexate patterns; pulmonary alveolar proteinosis (E) is unrelated. No logical flaws exist—the stem is internally consistent, provides adequate detail for a single best answer, and the key matches it. Medical accuracy is gold-standard: the HP pattern association is well-established in literature, the BAL profile is correctly characterized, and the rationale accurately distinguishes drug-induced injury from underlying rheumatoid lung disease. The item is clinically realistic and board-relevant. No modifications needed.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-003", "question": "A 32-year-old woman at 28 weeks gestation presents with severe preeclampsia. Despite magnesium sulfate and labetalol, she develops pulmonary edema requiring intubation. Echocardiography shows preserved ejection fraction of 65% with grade III diastolic dysfunction and elevated E/e' ratio of 18. Central venous pressure is 4 mmHg. Which pathophysiologic mechanism best explains her pulmonary edema?", "options": ["Systolic heart failure from peripartum cardiomyopathy", "Increased pulmonary capillary permeability from endothelial dysfunction", "Volume overload from iatrogenic fluid administration", "Diastolic dysfunction from acute afterload mismatch", "Mitral regurgitation from papillary muscle dysfunction"], "answer": "D", "answer_index": 3, "explanation": "Severe preeclampsia causes acute hypertensive crisis leading to afterload mismatch. The preserved EF with grade III diastolic dysfunction and elevated E/e' indicates heart failure with preserved ejection fraction due to impaired ventricular relaxation from acute pressure overload. The low CVP argues against volume overload. While endothelial dysfunction occurs in preeclampsia, the echocardiographic findings point to diastolic dysfunction as the primary mechanism. Peripartum cardiomyopathy would show reduced systolic function.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. Key discriminating clues: severe preeclampsia with pulmonary edema; echo showing preserved EF (65%), grade III diastolic dysfunction, and elevated E/e' (18); low CVP (4 mmHg). These findings establish heart failure with preserved ejection fraction (HFpEF) secondary to acute hypertensive afterload mismatch—a recognized preeclampsia complication. Option D correctly identifies diastolic dysfunction as the primary mechanism. Alternatives fail: A is excluded by preserved EF; B, while pathophysiologically present in preeclampsia, is superseded by direct echo evidence of cardiogenic edema; C contradicts low CVP and diastolic pattern; E lacks echo support. No internal contradictions or missing critical details. Medical accuracy: Echo parameters align with ASE criteria for HFpEF; pathophysiology reflects current consensus on preeclampsia-related cardiovascular complications. Item is clinically realistic and board-relevant. Minimal fix: None required.\",\"medical_accuracy_score\":  \"5\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. Key discriminating clues: severe preeclampsia with pulmonary edema; echo showing preserved EF (65%), grade III diastolic dysfunction, and elevated E/e' (18); low CVP (4 mmHg). These findings establish heart failure with preserved ejection fraction (HFpEF) secondary to acute hypertensive afterload mismatch—a recognized preeclampsia complication. Option D correctly identifies diastolic dysfunction as the primary mechanism. Alternatives fail: A is excluded by preserved EF; B, while pathophysiologically present in preeclampsia, is superseded by direct echo evidence of cardiogenic edema; C contradicts low CVP and diastolic pattern; E lacks echo support. No internal contradictions or missing critical details. Medical accuracy: Echo parameters align with ASE criteria for HFpEF; pathophysiology reflects current consensus on preeclampsia-related cardiovascular complications. Item is clinically realistic and board-relevant. Minimal fix: None required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-004", "question": "A 67-year-old man with ischemic cardiomyopathy (EF 25%) and cardiac resynchronization therapy-defibrillator presents after appropriate ICD shock for ventricular tachycardia. He is on maximally tolerated guideline-directed medical therapy including sacubitril-valsartan, carvedilol, spironolactone, and dapagliflozin. Electrophysiology study reveals scar-related reentrant VT from the inferolateral left ventricle. Catheter ablation is performed. Three months later, he has recurrent VT storm despite amiodarone. Which additional pharmacologic therapy has demonstrated mortality benefit in this specific population?", "options": ["Mexiletine", "Sotalol", "Ranolazine", "Quinidine", "Dofetilide"], "answer": "A", "answer_index": 0, "explanation": "Mexiletine, a class IB sodium channel blocker, when added to amiodarone in patients with recurrent VT despite amiodarone monotherapy, has shown reduction in VT recurrence and ICD shocks. The MEXICA trial demonstrated this combination's efficacy. Sotalol and dofetilide have proarrhythmic risks in low EF patients. Quinidine has significant toxicity and limited modern data. Ranolazine has some antiarrhythmic properties but lacks robust evidence in scar-related VT. Mexiletine's synergistic sodium channel blockade with amiodarone provides additional substrate modification.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: K (Miskeyed). Verdict: The keyed answer is factually incorrect based on the question's explicit criterion. The stem asks for therapy with 'demonstrated mortality benefit' in recurrent VT storm despite amiodarone post-ablation. While mexiletine was studied in the MEXICA trial for this exact scenario, the trial demonstrated reduced VT/VF recurrence, NOT mortality benefit (mortality endpoint was neutral and underpowered). This mischaracterization of trial outcomes is a critical medical inaccuracy. Key discriminating clues: ischemic cardiomyopathy (EF 25%), scar-related VT, VT storm refractory to amiodarone and ablation, maximal GDMT. These identify a high-risk population where antiarrhythmic escalation is considered, but no option has proven mortality benefit. Alternative options fail similarly: sotalol (SWORD trial showed increased mortality in low EF), dofetilide (proarrhythmic risk), quinidine (toxicity, no modern data), ranolazine (insufficient evidence). The question fatally conflates arrhythmia suppression with mortality benefit. Minimal fix: Replace 'mortality benefit' with 'reduction in ventricular arrhythmia recurrence' and correct the rationale to accurately state MEXICA's primary endpoint and lack of mortality effect.\",\"medical_accuracy_score\":   \"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: K (Miskeyed). Verdict: The keyed answer is factually incorrect based on the question's explicit criterion. The stem asks for therapy with 'demonstrated mortality benefit' in recurrent VT storm despite amiodarone post-ablation. While mexiletine was studied in the MEXICA trial for this exact scenario, the trial demonstrated reduced VT/VF recurrence, NOT mortality benefit (mortality endpoint was neutral and underpowered). This mischaracterization of trial outcomes is a critical medical inaccuracy. Key discriminating clues: ischemic cardiomyopathy (EF 25%), scar-related VT, VT storm refractory to amiodarone and ablation, maximal GDMT. These identify a high-risk population where antiarrhythmic escalation is considered, but no option has proven mortality benefit. Alternative options fail similarly: sotalol (SWORD trial showed increased mortality in low EF), dofetilide (proarrhythmic risk), quinidine (toxicity, no modern data), ranolazine (insufficient evidence). The question fatally conflates arrhythmia suppression with mortality benefit. Minimal fix: Replace 'mortality benefit' with 'reduction in ventricular arrhythmia recurrence' and correct the rationale to accurately state MEXICA's primary endpoint and lack of mortality effect.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-005", "question": "A 6-year-old boy presents with recurrent episodes of fever, cervical lymphadenopathy, aphthous stomatitis, and pharyngitis occurring every 4-6 weeks since age 2. Episodes resolve spontaneously within 5 days. Between episodes, he is completely well with normal growth. Laboratory studies during an episode show elevated CRP and ESR with normal complete blood count. Genetic testing for FMF, TRAPS, and HIDS mutations is negative. Which treatment has the highest likelihood of inducing complete remission?", "options": ["Colchicine prophylaxis", "Anakinra during episodes", "Single-dose corticosteroid at episode onset", "Tonsillectomy with or without adenoidectomy", "Cimetidine prophylaxis"], "answer": "D", "answer_index": 3, "explanation": "PFAPA syndrome (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis) is the most common periodic fever syndrome in children. While corticosteroids abort individual episodes, they may shorten the interval between attacks. Tonsillectomy (with or without adenoidectomy) achieves complete resolution in 63-95% of patients and is considered curative. Colchicine and cimetidine have variable efficacy for prophylaxis. Anakinra is reserved for refractory cases. The classic presentation with negative genetic testing and stereotypical episodes strongly supports PFAPA, where tonsillectomy offers the best chance of definitive cure.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V. Verdict: Correct best answer. The stem provides textbook PFAPA syndrome features: recurrent febrile episodes with aphthous stomatitis, pharyngitis, and cervical adenitis every 4-6 weeks since age 2, spontaneous 5-day resolution, complete inter-episode wellness with normal growth, normal CBC, and negative genetic testing for FMF, TRAPS, and HIDS. These findings uniquely identify PFAPA and exclude other periodic fevers. The question specifically targets complete remission, not episode abortion or frequency reduction. Tonsillectomy (D) is the only option with curative intent, supported by robust literature showing 63-95% complete resolution rates and is considered first-line surgical therapy. Alternative therapies are inferior for this outcome: colchicine (A) and cimetidine (E) provide variable prophylaxis with incomplete efficacy; single-dose corticosteroids (C) abort episodes but may paradoxically increase attack frequency and do not induce remission; anakinra (B) is reserved for refractory cases unresponsive to standard therapy. No logical flaws exist—the stem is fully sufficient, options are distinct and permit clear discrimination, and D is uniquely defensible as the best answer. Medical accuracy is gold-standard: fully consistent with current pediatric rheumatology consensus, ACR guidelines, and recent systematic reviews. No edits required.\",\n\"medical_accuracy_score\":   \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. The stem provides textbook PFAPA syndrome features: recurrent febrile episodes with aphthous stomatitis, pharyngitis, and cervical adenitis every 4-6 weeks since age 2, spontaneous 5-day resolution, complete inter-episode wellness with normal growth, normal CBC, and negative genetic testing for FMF, TRAPS, and HIDS. These findings uniquely identify PFAPA and exclude other periodic fevers. The question specifically targets complete remission, not episode abortion or frequency reduction. Tonsillectomy (D) is the only option with curative intent, supported by robust literature showing 63-95% complete resolution rates and is considered first-line surgical therapy. Alternative therapies are inferior for this outcome: colchicine (A) and cimetidine (E) provide variable prophylaxis with incomplete efficacy; single-dose corticosteroids (C) abort episodes but may paradoxically increase attack frequency and do not induce remission; anakinra (B) is reserved for refractory cases unresponsive to standard therapy. No logical flaws exist—the stem is fully sufficient, options are distinct and permit clear discrimination, and D is uniquely defensible as the best answer. Medical accuracy is gold-standard: fully consistent with current pediatric rheumatology consensus, ACR guidelines, and recent systematic reviews. No edits required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-006", "question": "A 45-year-old woman with systemic lupus erythematosus develops acute kidney injury with serum creatinine rising from 1.0 to 3.8 mg/dL over 2 weeks. Urinalysis shows 3+ protein, numerous RBC casts, and dysmorphic red cells. Complement levels are low. Kidney biopsy reveals diffuse proliferative glomerulonephritis (Class IV-G) with 40% cellular crescents, wire loop lesions, and activity index of 14/24 with chronicity index of 2/12. Anti-dsDNA antibody titer is markedly elevated. Which induction regimen has demonstrated superior renal response rates in this clinical scenario?", "options": ["Mycophenolate mofetil plus glucocorticoids", "Cyclophosphamide (Euro-Lupus protocol) plus glucocorticoids", "Voclosporin plus mycophenolate mofetil plus glucocorticoids", "Rituximab plus mycophenolate mofetil plus glucocorticoids", "Belimumab plus cyclophosphamide plus glucocorticoids"], "answer": "C", "answer_index": 2, "explanation": "The AURORA trial demonstrated that voclosporin added to mycophenolate mofetil and low-dose glucocorticoids achieved significantly higher complete renal response rates (41% vs 23%) at 52 weeks compared to MMF and glucocorticoids alone in active lupus nephritis. This triple therapy showed benefit across Class III, IV, and V lupus nephritis. While MMF and cyclophosphamide are established induction agents, the addition of voclosporin (a novel calcineurin inhibitor) provides superior efficacy. Rituximab and belimumab combinations lack the same level of evidence for superior renal response in this setting.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. This item tests knowledge of recent trial data in severe lupus nephritis. Key stem clues—diffuse proliferative Class IV-G histology with 40% cellular crescents, high activity index (14/24), and acute kidney injury—define a high-risk population where superior induction therapy is critical. The AURORA trial definitively demonstrated that voclosporin added to mycophenolate mofetil and low-dose glucocorticoids achieved significantly higher complete renal response rates (41% vs 23%) at 52 weeks compared to MMF and steroids alone in active lupus nephritis, including Class IV disease. Each distractor is appropriately flawed: A lacks superiority claim; B represents standard therapy but without demonstrated superiority over MMF; D (rituximab) was not superior in the LUNAR trial; E combines belimumab with cyclophosphamide, a regimen not tested in BLISS-LN. No logical flaws exist: the stem provides sufficient histologic and clinical detail, the question clearly asks about demonstrated superiority, and option C uniquely matches the trial evidence. Medical accuracy is excellent: the AURORA trial data is accurately represented, voclosporin is FDA-approved, and the histologic descriptions conform to ISN/RPS classification. No revisions required.\",\"medical_accuracy_score\":   \"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. This item tests knowledge of recent trial data in severe lupus nephritis. Key stem clues—diffuse proliferative Class IV-G histology with 40% cellular crescents, high activity index (14/24), and acute kidney injury—define a high-risk population where superior induction therapy is critical. The AURORA trial definitively demonstrated that voclosporin added to mycophenolate mofetil and low-dose glucocorticoids achieved significantly higher complete renal response rates (41% vs 23%) at 52 weeks compared to MMF and steroids alone in active lupus nephritis, including Class IV disease. Each distractor is appropriately flawed: A lacks superiority claim; B represents standard therapy but without demonstrated superiority over MMF; D (rituximab) was not superior in the LUNAR trial; E combines belimumab with cyclophosphamide, a regimen not tested in BLISS-LN. No logical flaws exist: the stem provides sufficient histologic and clinical detail, the question clearly asks about demonstrated superiority, and option C uniquely matches the trial evidence. Medical accuracy is excellent: the AURORA trial data is accurately represented, voclosporin is FDA-approved, and the histologic descriptions conform to ISN/RPS classification. No revisions required.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-007", "question": "A 72-year-old man is admitted to the ICU with septic shock from pneumonia. Despite adequate fluid resuscitation and norepinephrine at 0.5 mcg/kg/min, MAP remains 58 mmHg. Echocardiography shows hyperdynamic left ventricle with EF 75%, small LV cavity, and IVC diameter of 0.8 cm with >50% respiratory variation. Lactate is 6.2 mmol/L. Which vasopressor strategy is most appropriate?", "options": ["Add vasopressin 0.03 units/min", "Add epinephrine infusion", "Add phenylephrine infusion", "Add angiotensin II infusion", "Increase norepinephrine to maximum dose before adding second agent"], "answer": "A", "answer_index": 0, "explanation": "Current sepsis guidelines recommend adding vasopressin (up to 0.03 units/min) as the second-line vasopressor when norepinephrine fails to achieve target MAP, typically when norepinephrine exceeds 0.25-0.5 mcg/kg/min. Vasopressin acts via V1 receptors independent of catecholamine pathways, which may be downregulated in sepsis. The VASST trial showed potential mortality benefit in less severe septic shock. The echocardiographic findings suggest adequate volume status (small IVC with variation indicates fluid responsiveness is exhausted). Angiotensin II is reserved for refractory vasodilatory shock after multiple agents. Phenylephrine may reduce cardiac output.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: C (Contradiction). Verdict: Keyed answer aligns with sepsis guidelines but item contains fatal flaw. The stem presents a 72-year-old with refractory septic shock on norepinephrine 0.5 mcg/kg/min with MAP 58. Guidelines support adding vasopressin (option A) as the second agent at this stage, making it the defensible best answer. However, the echo finding of IVC 0.8 cm with >50% respiratory variation directly contradicts the statement 'adequate fluid resuscitation,' as these parameters indicate ongoing fluid responsiveness and suggest hypovolemia rather than euvolemia. This internal inconsistency makes the clinical scenario incoherent—if the patient remains fluid responsive, the next step should be additional fluids, not vasopressor escalation. The rationale compounds this error by misinterpreting the IVC findings as supporting adequate volume status. While options B-E are appropriately less favored per guidelines (epinephrine less preferred as second agent, phenylephrine risks cardiac output reduction, angiotensin II is third-line, and maximizing norepinephrine alone is not recommended), the contradictory fluid status assessment prevents unambiguous answer selection. Minimal fix: Remove IVC collapsibility data or add explicit justification for withholding fluids despite these findings (e.g., pulmonary edema on chest X-ray).\",\"medical_accuracy_score\":   \"3\",\"logical_validity\": false,\"logical_false_reason\": \"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: C (Contradiction). Verdict: Keyed answer aligns with sepsis guidelines but item contains fatal flaw. The stem presents a 72-year-old with refractory septic shock on norepinephrine 0.5 mcg/kg/min with MAP 58. Guidelines support adding vasopressin (option A) as the second agent at this stage, making it the defensible best answer. However, the echo finding of IVC 0.8 cm with >50% respiratory variation directly contradicts the statement 'adequate fluid resuscitation,' as these parameters indicate ongoing fluid responsiveness and suggest hypovolemia rather than euvolemia. This internal inconsistency makes the clinical scenario incoherent—if the patient remains fluid responsive, the next step should be additional fluids, not vasopressor escalation. The rationale compounds this error by misinterpreting the IVC findings as supporting adequate volume status. While options B-E are appropriately less favored per guidelines (epinephrine less preferred as second agent, phenylephrine risks cardiac output reduction, angiotensin II is third-line, and maximizing norepinephrine alone is not recommended), the contradictory fluid status assessment prevents unambiguous answer selection. Minimal fix: Remove IVC collapsibility data or add explicit justification for withholding fluids despite these findings (e.g., pulmonary edema on chest X-ray).", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-008", "question": "A 29-year-old primigravida at 34 weeks gestation presents with sudden-onset severe headache and right-sided weakness. Blood pressure is 178/112 mmHg. CT head shows left parietal intracerebral hemorrhage with surrounding edema. MRV demonstrates absence of flow in the superior sagittal sinus and left transverse sinus consistent with cerebral venous thrombosis. Platelet count is 82,000/μL, LDH is elevated, and peripheral smear shows schistocytes. Which is the most appropriate immediate management?", "options": ["Emergent cesarean delivery followed by therapeutic anticoagulation", "Therapeutic anticoagulation with unfractionated heparin", "Platelet transfusion followed by decompressive craniectomy", "Plasma exchange followed by anticoagulation", "Magnesium sulfate and antihypertensives with delayed anticoagulation"], "answer": "A", "answer_index": 0, "explanation": "This patient has cerebral venous thrombosis complicated by hemorrhagic transformation in the setting of HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) evidenced by thrombocytopenia, elevated LDH, and schistocytes. The definitive treatment for HELLP is delivery. While anticoagulation is standard for CVT even with hemorrhage, the underlying HELLP syndrome will not resolve without delivery and may worsen, increasing bleeding risk. Emergent cesarean delivery addresses the root cause, after which therapeutic anticoagulation can be safely initiated. Plasma exchange is for TTP, not HELLP. Delaying anticoagulation without addressing HELLP is inappropriate.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: M (Multiple answers defensible). Verdict: Keyed answer not uniquely determinable. The stem presents CVT with hemorrhagic transformation in a pregnant patient with thrombocytopenia, hemolysis, and severe hypertension. Key clues: 34 weeks gestation, platelets 82k, schistocytes, elevated LDH, BP 178/112, left parietal ICH. The rationale assumes HELLP syndrome, but liver enzymes—the 'L' in HELLP—are not provided, making the diagnosis speculative. This underspecification yields two defensible pathways: (1) Treat CVT emergently with unfractionated heparin (Option B), which is guideline-recommended even with hemorrhage; or (2) Emergent cesarean for presumed HELLP (Option A) before anticoagulation. Current neurocritical care guidelines prioritize immediate anticoagulation for CVT regardless of hemorrhagic transformation, making Option B clinically more appropriate. The keyed answer A contradicts these standards by delaying anticoagulation. Minimal fix: Add AST/ALT values confirming HELLP and specify maternal/neurologic instability (e.g., herniation risk) to justify emergent delivery as the immediate priority.\",\"medical_accuracy_score\":   \"3\",\"logical_validity\": false,\"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: M (Multiple answers defensible). Verdict: Keyed answer not uniquely determinable. The stem presents CVT with hemorrhagic transformation in a pregnant patient with thrombocytopenia, hemolysis, and severe hypertension. Key clues: 34 weeks gestation, platelets 82k, schistocytes, elevated LDH, BP 178/112, left parietal ICH. The rationale assumes HELLP syndrome, but liver enzymes—the 'L' in HELLP—are not provided, making the diagnosis speculative. This underspecification yields two defensible pathways: (1) Treat CVT emergently with unfractionated heparin (Option B), which is guideline-recommended even with hemorrhage; or (2) Emergent cesarean for presumed HELLP (Option A) before anticoagulation. Current neurocritical care guidelines prioritize immediate anticoagulation for CVT regardless of hemorrhagic transformation, making Option B clinically more appropriate. The keyed answer A contradicts these standards by delaying anticoagulation. Minimal fix: Add AST/ALT values confirming HELLP and specify maternal/neurologic instability (e.g., herniation risk) to justify emergent delivery as the immediate priority.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-009", "question": "A 14-year-old girl presents with 3 months of progressive fatigue, arthralgia, and facial rash. Laboratory evaluation reveals ANA 1:1280 (homogeneous pattern), anti-dsDNA positive, anti-Smith positive, C3 45 mg/dL (normal 90-180), C4 6 mg/dL (normal 10-40), and anti-C1q antibodies positive. Urinalysis shows 2+ protein and 10-15 RBCs/hpf. She is diagnosed with juvenile-onset systemic lupus erythematosus. The presence of anti-C1q antibodies in this patient most specifically predicts which disease manifestation?", "options": ["Neuropsychiatric lupus", "Proliferative lupus nephritis", "Antiphospholipid syndrome", "Lupus pneumonitis", "Autoimmune hemolytic anemia"], "answer": "B", "answer_index": 1, "explanation": "Anti-C1q antibodies have the highest specificity for lupus nephritis, particularly proliferative forms (Class III/IV). Studies demonstrate that anti-C1q antibodies have a negative predictive value approaching 100% for active renal disease-their absence essentially excludes active nephritis. The combination of anti-C1q with anti-dsDNA antibodies and low complement strongly predicts proliferative nephritis. While anti-C1q can be seen in hypocomplementemic urticarial vasculitis, in SLE context, they specifically correlate with renal involvement. Anti-ribosomal P antibodies are more associated with neuropsychiatric lupus.", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. The stem clearly establishes juvenile SLE with active serology (high ANA, anti-dsDNA, anti-Smith, low C3/C4) and renal involvement (proteinuria, hematuria). The question asks what anti-C1q antibodies most specifically predict. Key discriminating clue is the established association between anti-C1q and proliferative lupus nephritis (Class III/IV), with high specificity and negative predictive value for active renal disease. Option B aligns perfectly with current rheumatology consensus and major guidelines. Alternative options are appropriately excluded: neuropsychiatric lupus (A) associates with anti-ribosomal P, not anti-C1q; antiphospholipid syndrome (C) requires distinct antibodies; lupus pneumonitis (D) and autoimmune hemolytic anemia (E) lack specific anti-C1q associations. No logical flaws: the stem provides sufficient context, options are mutually exclusive, and the key is unambiguously supported. Medical accuracy is excellent—the anti-C1q-nephritis relationship is well-validated, and the rationale correctly notes the negative predictive value and complement interplay. No contradictions or underspecification. Minimal fix: none required; item is board-ready.\",\"medical_accuracy_score\":  \"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The stem clearly establishes juvenile SLE with active serology (high ANA, anti-dsDNA, anti-Smith, low C3/C4) and renal involvement (proteinuria, hematuria). The question asks what anti-C1q antibodies most specifically predict. Key discriminating clue is the established association between anti-C1q and proliferative lupus nephritis (Class III/IV), with high specificity and negative predictive value for active renal disease. Option B aligns perfectly with current rheumatology consensus and major guidelines. Alternative options are appropriately excluded: neuropsychiatric lupus (A) associates with anti-ribosomal P, not anti-C1q; antiphospholipid syndrome (C) requires distinct antibodies; lupus pneumonitis (D) and autoimmune hemolytic anemia (E) lack specific anti-C1q associations. No logical flaws: the stem provides sufficient context, options are mutually exclusive, and the key is unambiguously supported. Medical accuracy is excellent—the anti-C1q-nephritis relationship is well-validated, and the rationale correctly notes the negative predictive value and complement interplay. No contradictions or underspecification. Minimal fix: none required; item is board-ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed126-010", "question": "A 52-year-old man with no prior cardiac history presents with acute anterior STEMI. Primary PCI reveals 100% occlusion of the proximal LAD with TIMI 0 flow. After successful stenting with TIMI 3 flow restoration, he develops cardiogenic shock with blood pressure 78/52 mmHg, heart rate 112 bpm, and cardiac index 1.6 L/min/m². Echocardiography shows akinesis of the anterior wall, apex, and septum with EF 20%. He is started on norepinephrine and dobutamine. Despite escalating support, he remains in refractory shock. Which mechanical circulatory support device provides the greatest degree of left ventricular unloading?", "options": ["Intra-aortic balloon pump", "Impella CP", "TandemHeart", "Veno-arterial ECMO", "Impella 5.5"], "answer": "E", "answer_index": 4, "explanation": "Impella 5.5 provides up to 5.5 L/min of forward flow and the greatest degree of LV unloading among the options by actively aspirating blood from the LV and ejecting it into the ascending aorta. This reduces LV end-diastolic pressure, wall stress, and myocardial oxygen demand while maintaining systemic perfusion. VA-ECMO provides excellent systemic support but increases LV afterload and may worsen pulmonary edema without LV venting. TandemHeart provides good support but requires transseptal puncture. Impella CP provides only 3-4 L/min. IABP provides modest afterload reduction with minimal flow augmentation (0.5 L/min).", "generator_model": "claude-opus-4-5-20251101", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. This item tests knowledge of LV unloading properties in refractory post-MI cardiogenic shock. Key discriminating features: persistent shock despite norepinephrine/dobutamine, EF 20%, extensive anterior wall akinesis. The query specifically isolates 'greatest LV unloading' as the sole decision criterion. Impella 5.5 (E) is uniquely correct: it actively aspirates blood directly from the LV cavity into the ascending aorta at 5.5 L/min, maximally reducing LV end-diastolic volume, pressure, and myocardial oxygen demand. Distractors are appropriately excluded: IABP (A) offers minimal flow augmentation; Impella CP (B) provides only 3-4 L/min; TandemHeart (C) drains the left atrium indirectly; VA-ECMO (D) increases LV afterload. No contradictions or critical omissions impair answer selection. Medical accuracy is excellent and guideline-concordant. Minimal fix: None required; item is board-examination ready.\",\"medical_accuracy_score\":  \t\"5\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. This item tests knowledge of LV unloading properties in refractory post-MI cardiogenic shock. Key discriminating features: persistent shock despite norepinephrine/dobutamine, EF 20%, extensive anterior wall akinesis. The query specifically isolates 'greatest LV unloading' as the sole decision criterion. Impella 5.5 (E) is uniquely correct: it actively aspirates blood directly from the LV cavity into the ascending aorta at 5.5 L/min, maximally reducing LV end-diastolic volume, pressure, and myocardial oxygen demand. Distractors are appropriately excluded: IABP (A) offers minimal flow augmentation; Impella CP (B) provides only 3-4 L/min; TandemHeart (C) drains the left atrium indirectly; VA-ECMO (D) increases LV afterload. No contradictions or critical omissions impair answer selection. Medical accuracy is excellent and guideline-concordant. Minimal fix: None required; item is board-examination ready.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]